FinlandFinland

Researchers find that creation of induced pluripotent stem cells is linked to genetic abnormalities

03.03.2011

Helsinki/Toronto – Induced pluripotent stem cells from a patient’s own cells must be screened for genetic failures before any clinical use, new research from Finnish and Canadian researchers suggest. In Nature the researchers from Mount Sinai Hospital and Biomedicum Stem Cell Center at University of Helsinki under Timo Otonkoski report that the reprogramming process for generating iPS cells (i.e., cells that can then be 'coaxed' into becoming a variety of cell types for use in regenerative medicine) is associated with inherent DNA damage. Carrying out genome-wide comparative SNP analyses of human iPS cells with their respective parental cells, they identified genetic rearrangements and copy number variations in each of the assessed cell lines. "Our analysis shows that these genetic changes are a result of the reprogramming process itself, which raises the concern that the resultant cell lines are mutant or defective," said Dr. Nagy, a Senior Investigator at Mount Sinai Hospital. "These mutations could alter the properties of the stem cells, affecting their applications in studying degenerative conditions and screening for drugs to treat diseases.“ In the longer term, this discovery has important implications in the use of these cells for replacement therapies in regenerative medicine. "Our study highlights the need for rigorous characterization of generated iPS lines, especially since several groups are currently trying to enhance reprogramming efficiency," said Dr. Samer Hussein at Biomedicinium Stem Cell Center. "For example, increasing the efficiency of reprogramming may actually reduce the quality of the cells in the long run, if genomic integrity is not accurately assessed." Both teams found that iPS cells had more genetic abnormalities than their originating cells and embryonic stem cells. Interestingly, however, the simple process of growing the freshly generated iPS cells for a few weeks selected against the highly mutant cell lines, and thus most of the genetic abnormalities were eventually 'weeded out.'

FinlandFinland

19.09.2009

Helsinki – According to a new survey, Finnish high-tech growth companies raised almost a51m in the first half of 2009, 17% down on the first half of 2008. Second quarter funding decreased by more than 50% from the same period in...

FinlandFinland

13.07.2009

Helsinki – The Finnish government has announced plans to introduce tax incentives for companies with high research and development activities. At the end of June, a working group from the Ministry of Employment and Economy (MEE)...

FinlandFinland

05.06.2009

Espoo – Finnish pharmaceutical and dia­gnostics company OrionA/S has agreed to pay Abbott US$18m to re-acquire the rights to the intravenous formulation of its heart failure treatment levosimendan, which is marketed as...

FinlandFinland

29.04.2009

Helsinki – The Finnish Funding Agency for Technology and Innovation (Tekes), and the forest-based industry organised in the Finnish Forest Cluster have announced the five-year-research programme “Future Refinery” (FuBio), a...

FinlandFinland

21.02.2009

Helsinki – The Finnish Government has set up a new innovation policy. As its starting point, the Science and Technology Policy Council adopted the report “Review2008” in December, which outlines Finland’s new national strategy...

FinlandFinland

07.10.2008

A Helsinki – The causes of human anxiety disorders are largely unexplored, so there are currently no targeted drugs available for treatment. That’s why Finnish researchers from the Academy of Finland Research Programme on...

FinlandFinland

14.08.2008

Helsinki – A proposal for national innovation strategy has laid down new outlines for reforming Finland’s innovation policy, and has presented an action programme for their implementation. The proposal was submitted on June 12th...

FinlandFinland

20.05.2008

Helsinki – The Technology Academy Finland, an independent foundation established by Finnish industry, has announced the 4 finalists for the 2008 Millenium Technology Prize, which is awarded for technological innovation that...

FinlandFinland

19.03.2008

Helsinki – A study conducted by the research arm of the global assurance firm Allianz SE for the Lisbon Council, a Brussels-based think tank, has concluded that Finland already fulfills all of the criteria for the so-called...

FinlandFinland

19.03.2008

Helsinki – An international research team under Prof. Rasmus Nielsen from Copenhagen University has discovered that Europeans carry significantly more deleterious mutations in their genomes than Africans. The results are based on...

Displaying results 21 to 30 out of 96

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-finland/browse/2/article/researchers-find-that-creation-of-induced-pluripotent-stem-cells-is-linked-to-genetic-abnormalities.html

Events

All Events

Stock list

All quotes

TOP

  • SANTHERA74.95 CHF10.30%
  • BIOTEST80.50 EUR6.83%
  • WILEX2.22 EUR5.71%

FLOP

  • 4SC1.20 EUR-6.25%
  • VITA 343.78 EUR-2.83%
  • EPIGENOMICS3.12 EUR-2.50%

TOP

  • WILEX2.22 EUR177.5%
  • MAGFORCE6.50 EUR17.1%
  • SANTHERA74.95 CHF10.2%

FLOP

  • VITA 343.78 EUR-24.6%
  • MOLOGEN7.80 EUR-19.3%
  • PAION2.40 EUR-17.2%

TOP

  • SANTHERA74.95 CHF3647.5%
  • CO.DON2.50 EUR212.5%
  • PAION2.40 EUR182.4%

FLOP

  • CYTOS0.27 CHF-93.3%
  • MEDIGENE4.60 EUR-67.7%
  • THERAMETRICS0.08 CHF-46.7%

No liability assumed, Date: 19.08.2014


Current issue

All issues

Product of the week

Products